ARCHIVES

FDA Hears More Criticism On Cancer Drug Endpoints; Joint Conferences On Criteria Recommended

This article is from The Cancer Letter archive.

Vol. 15 No. 30 | July 28, 1989

Download PDF Visit The Full Archive

Related Articles

ASCO Strategic Plan Seeks To Increase Value to Members, Public

May 24, 2002

FDA Approves Herceptin For HER2+ Metastatic Stomach Cancers

October 22, 2010

Advisors Approve New Grant Programs In Breast Pre-Malignancy, Lung Inflammation

November 17, 2006

NCI Clarifies P01 Grant Application Dates

September 13, 1996

Chest X-Rays In BRCA Carriers May Increase Cancer Risk

July 28, 2006

DCT Board Delays Action On Protein Index, Refuses Support for Cow Study, Approves Various Concepts

October 16, 1981